ABSTRACT
A utilização de células-tronco na reparação de lesões tem sido extensivamente investigada. Neste estudo, examinamos os efeitos terapêuticos de dois transplantes (12x106 céls/transplante) de células-tronco mesenquimais alogênicas derivadas do tecido adiposo (CTDAs) em 11 cães com lesões crônicas traumáticas toracolombares da medula espinhal. As CTDAs foram foram cultivadas in vitro, a proliferação e a viabilidade foram avaliadas. As suspensões foram expandidas e administradas no espaço intradural com intervalo de uma semana entre transplantes. Os cães foram submetidos à avaliações clínicas, laboratoriais, radiográficas, tomográficas, sensitivas, motoras e cistométricas. A maioria dos animais não tinha raça definida (63,63%), mesma proporção para o acometimento de fêmeas e foi observada predominância de fratura com subluxação vertebral (81,81%). Na comparação dos cães pré e pós-transplante não foram observadas alterações hematológicas e três animais (27,27%) apresentaram cistite bacteriana. Em relação a sensibilidade, motricidade e cistometria, também não houve alterações significativas dos índices antes e pós transplantes, sendo observado a ausência nociceptiva na maioria dos animais (72,73%), paraplegia e incontinência urinária na mesma proporção. Neste estudo concluiu-se que o protocolo utilizado de transplante de CTDAs, demonstrou ser um tratamento seguro para cães com lesão medular crônica, com melhora discreta da funcionalidade vesical, porém sem melhora clínica significativa.(AU)
The use of stem cells in injury repair has been extensively investigated. In this study, we examined the therapeutic effects of two transplants (12x106 cells/transplantation) of allogenic adipose-derived stem cells (ASCs) in 11 dogs with chronic spinal cord injury. ASC were cultured in vitro, proliferation and cell viability were evaluated. Cell suspensions were prepared and administered in the intradural space, with a one-week interval between transplants. The animals were submitted to clinical, laboratory, radiographic, tomographic, sensory, motor and cystometric evaluations. Most of the animals were not a breed defined (63.63%), the same proportion for females affected, predominance of vertebral subluxation fracture was observed (81.81%). Before and after the transplants no hematological changes were observed, three animals (27.27%) presented bacterial cystitis, and in relation to motor, cystometry and sensitivity, no improvement was observed; the rates were maintained before and after transplants, predominance of nociceptive absence in most animals (72.73%), and paraplegia and urinary incontinence in the same proportion. In this study it was concluded that the use of ADSCs for the treatment of dogs with chronic spinal cord injury is safe, with a slight improvement in bladder function, but without significantly clinical improvement.(AU)
Subject(s)
Animals , Dogs , Spinal Cord Compression/surgery , Spinal Cord Compression/veterinary , Spinal Cord Injuries/surgery , Spinal Cord Injuries/veterinary , Mesenchymal Stem Cell Transplantation/veterinary , Dogs/injuriesABSTRACT
Sequential monitoring of chimerism after hematopoietic stem cell transplantation is important for disease prognosis, improving transplantation success rate, and reducing relapses of the original diseases. The application of molecular genetic markers in combination with quantitative PCR to the assessment of chimerism,in particularly the dynamic quantitative analysis of lineage-specific chimerism, can provide important guidance for clinical practice.
ABSTRACT
Objective To investigate the clinical effect of rhG-CSF combined transplantation of autologous bone marrow mesenchymal stem cells on cerebral infarction. Methods 42 acute cerebral infarction patients were randomly divided into tow groups: Injection rhGCSF combined autologous bone marrow mesenchymal stem cells group(treatment group, n=20)and conventionality therapy group(control group, n=22).The efficacy was assessed by National Institutes of Health Stroke Scale(NIHSS), Barthel Index(BI)and diffusion-weighted imaging(DWI),perfusion-weighted imaging(PWI)at baseline and the 3rd month after treatment. Result The scores of NHISS and BI treatment group were 4.8±2.0 and 78.5±7.2 respectively. while were 7.2±2.4 and 56.1±6.3 in control group at the 3rd month after treatment. The difference were significant(P＜0.01).PWI in treatment group Was higher than that in control group. There was no significant side-effect in treatment group. Conclusion rHG-CSF combined autologous bone marrow mesenchymal stem cells is a safe, efficient treatment for acute cerebral infarction patients, which is a better way than conventionality therapy.